Sienna Biopharmaceuticals to Present at J.P. Morgan Healthcare Conference

WESTLAKE VILLAGE, Calif., Jan. 04, 2018 -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the 36^th Annual J.P. Morgan Healthcare Conference, Wednesday, Jan. 10, 2018, 11:30 a.m. PST, in  San Francisco.

The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at Investors.SiennaBio.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

For more information, visit the Company’s website at www.SiennaBio.com.

Contact (Investors and Media):

Ric Peterson
Chief Financial Officer
[email protected]
818-629-2232

Sean Andrews
Senior Director, Investor Relations
[email protected]
818-629-2244